

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

ACC-MESO-4

RRID:CVCL_5114

Type: Cell Line

Proper Citation

RRID:CVCL_5114

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5114

Proper Citation: RRID:CVCL_5114

Description: Cell line ACC-MESO-4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pleural epithelioid mesothelioma

Defining Citation: [PMID:16630136](#), [PMID:17270034](#), [PMID:21245096](#), [PMID:25902174](#), [PMID:26011428](#), [PMID:28553954](#)

Comments: Population: Japanese.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: ACC-MESO-4

Synonyms: ACC-Meso-4, MESO-4

Cross References: CLO:CLO_0050083, BioSample:SAMN03471959, cancercellines:CVCL_5114, Cosmic:877274, Cosmic:1481541, Cosmic:2759003, Cosmic:2759232, FANTOM5_SSTAR:10494-107B8, GEO:GSM551968, GEO:GSM850297, IARC_TP53:24549, Progenetix:CVCL_5114, RCB:RCB2293, Wikidata:Q54608246

ID: CVCL_5114

Record Creation Time: 20220427T215127+0000

Record Last Update: 20260905T184435+0000

Ratings and Alerts

No rating or validation information has been found for ACC-MESO-4.

No alerts have been found for ACC-MESO-4.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kouro T, et al. (2025) Improvement in the function of self-activating chimeric antigen receptor by replacing the linker sequence. *Frontiers in immunology*, 16, 1502607.

Hirai S, et al. (2024) Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells. *Molecular cancer therapeutics*, 23(2), 212.

Kouro T, et al. (2024) Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1. *International journal of cancer*, 154(10), 1828.

Abukar A, et al. (2021) Double-Stranded RNA Structural Elements Holding the Key to Translational Regulation in Cancer: The Case of Editing in RNA-Binding Motif Protein 8A. *Cells*, 10(12).

Yang H, et al. (2021) NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. *Cancers*, 13(7).

Yang H, et al. (2020) Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. *Cancers*, 12(8).

Xu D, et al. (2019) Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. *Cancers*, 11(10).